The European pharmaceutical association Medicines for Europe, the Ministry of Health, and the Association of Ukrainian Pharmaceutical Manufacturers (AVLU) have signed a memorandum of partnership in the field of critical medicines. The memorandum was signed on the sidelines of the Ukraine Recovery Conference (URC2025) in Rome last week.
According to Adrian Van Den Goevaert, CEO of Medicines for Europe, Ukraine’s participation in the Critical Medicines Alliance and its experience in sharing responses, together with regulatory integration into EU systems based on alignment with EU technical and procedural rules, anti-corruption measures, the creation of an independent medicines agency in Ukraine, and mutual recognition of GMP certificates are becoming key priorities for EU-Ukraine pharmaceutical cooperation.
For his part, Anatoliy Reder, CEO of the pharmaceutical company Interchem (Odessa), noted that the memorandum will enable Ukrainian pharmaceutical companies to participate in the production of active pharmaceutical ingredients (APIs) for EU countries.
“The memorandum shows that Ukraine is highly developed in the field of pharmaceutical production and is ready to participate in supplying critical medicines to EU countries. We already have certain positions from the list of critical medicines and can very quickly ensure the production of the rest. We can produce APIs in the quantities required by the EU,” he said.
According to Reder, the production of APIs and drugs from the critical list will be convenient for both Ukraine and the EU.
“Ukraine has a highly developed and modern production control system. The requirements for the production of medicines in Ukraine are sometimes higher than in European countries, so we can ensure reliable supplies of high-quality products,” he said.
At the same time, Reder noted that in order to launch a project for the production of critical medicines, European manufacturers need support from European official bodies so that they can include Ukrainian production sites in their dossiers as additional sources of APIs.
Medicines for Europe, MEMORANDUM, Ministry of Health, PARTNERSHIP, PHARMACEUTICAL MANUFACTURERS
